This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Merit Medical Receives CE Marking For Prostatic Artery Embolization For Embosphere(R) Microspheres

Stocks in this article: MMSI

SOUTH JORDAN, Utah, March 7, 2013 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (Nasdaq:MMSI), a leading manufacturer and marketer of proprietary implantable as well as disposable devices used primarily in cardiology, radiology and endoscopy, today announced that it has received CE Marking ( Conformité Européenne) in the European Union to market its line of Embosphere® Microspheres for embolization of the prostate gland for relief of symptoms related to Benign Prostatic Hyperplasia (BPH).

Moderate to severe lower urinary tract symptoms (LUTS) due to BPH afflict approximately 50% of men aged 65 and older. At around age 50, the prostate gland—through which the urethra passes—grows large enough to constrict the urethra. For patients, quality of life decreases due to frequent urges to urinate and insufficient voiding. In some patients, these symptoms interrupt normal sleeping patterns, further degrading their quality of life. Ultimately BPH can cause acute urinary retention. Current treatment solutions include pharmacotherapy options such as 5-alpha reductase inhibitors and/or alpha-adrenergic blockers. Surgical interventions such as trans urethral resection of the prostate (TURP), prostatectomy or energy-based treatments such as laser or microwave are also options.

Prostatic artery embolization selectively blocks blood flow to the prostate resulting in reduced organ volume and reduced urethral stricture. Clinical data has demonstrated that patients achieve durable symptom relief while avoiding the complications and side effects associated with surgical or energy-based procedures and pharmacotherapy.

Consistent with its leadership role among interventional radiologists, Merit will sponsor a Center of Excellence training program at a number of leading hospitals in Europe beginning this year to facilitate physician training. The FDA has also approved an Investigational Device Exemption for Merit's international, multi-center, randomized clinical trial that will compare the results of prostatic artery embolization to transurethral resection of the prostate (TURP) for treatment of BPH.

"Embolotherapy has long been recognized as an option for patients who seek an alternative to surgical procedures and pharmacotherapy to resolve their symptoms," said Fred P. Lampropoulos, Merit's Chairman and Chief Executive Officer. "Embosphere enjoys an exceptional reputation in IR procedures such as Uterine Fibroid Embolization. Merit is delighted to expand Embosphere's reputation and utility with the CE Mark for prostatic artery embolization."

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,620.65 +263.78 1.52%
S&P 500 2,038.86 +25.97 1.29%
NASDAQ 4,709.3320 +65.02 1.40%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs